SI2 SUBJECT INDEX
prevalence of, 249–251
schizophrenia with, 534
self-help for, 141
social phobia, 278–289
somatization disorder vs., 357
specifi c phobias, 289–298
Anxiety neurosis, 19
Anxiety sensitivity
in panic disorder, 270–271
in substance use disorders,
410
Anxious-ambivalent attachment,
207
Anxious apprehension, 249
Aphasia, 687, 701, 705
Apo E gene, 707
Appearance, assessment of, 95
Apperceptive gnosia, 687
Applied behavior analysis,
640–641
Applied tension, 296
Approach emotions, 58
Apraxia, 688, 701, 705
Archetypes, 20
Aricept, 711
Aripiprazole, 229
Arousal
in anxiety disorders, 251
in dissociative amnesia, 336
generalized anxiety disorder
and, 255
in posttraumatic stress
disorder, 311, 320,
324–325
sexual, 482
sexual, disorders in, 499–500
Arousal disruption theory, 336
Asperger’s disorder, 635–638
Assertive community treatment,
562
Assessment, 88–105
baseline, 179
of dangerousness, 730–731
defi nition of, 73
follow-up, 179–180, 181
for insanity defense, 726
interactive process of,
104–105
of mental status, 97–98
of neurological and biological
factors, 89–94
neuropsychological testing,
93–94
outcome, 179
of paraphilias, 489–490
of personality disorders, 571
of psychological factors,
94–101
of psychological functioning,
98–101
racial/ethnic issues in,
144–145
of sexual dysfunctions,
509–510
of social factors, 102–104
Associative agnosia, 687–688
Asylums, 14, 15–16Ataque de nervios, 264–265
Atenolol, 423
Ativan, 407
Atomoxetine, 666
Attachment style, 24–25, 28–29
child maltreatment and, 62
depression and, 206–207
in personality disorders,
576–577
Attention, 53
aging and, 684–685
biases in, depression and, 203
defi cits in schizophrenia, 524
in delirium, 689
in depersonalization disorder,
342
emotions and bias in, 56–57
in schizophrenia, 547–548
in somatization disorder, 357
Attention-defi cit/hyperactivity
disorder (ADHD), 655–660
brain systems in, 660–661
feedback loops in, 664–665,
665f
genetic factors in, 661–662
methylphenidate for, 116
oppositional defi ant disorder
vs., 655
Ritalin for, 394
substance use disorder and,
387–388
treatment of, 666–669
Attibutional style, 204–205
Attitude, 55
Attributions, 56–57
in attention-defi cit/hyperactivity
disorder, 663
in depersonalization disorder,
342–343
depressive attributional style,
204–205, 204t
in posttraumatic stress
disorder, 324
in schizophrenia, 548–549
Attrition, 176–177
Atypical antipsychotics, 113,
557–558
Atypical depression, 196
Autism spectrum disorders,
633–641
Asperger’s disorder, 635–638
autistic disorder, 163, 282,
644–646
neurological factors in,
638–639
psychological factors in,
639
social factors in, 639–640
treatment of, 640–641
Autistic disorder (autism), 163,
633–635
Asperger’s disorder vs., 637
social phobia and, 282
Autistic savants, 634–635
Automatic negative thoughts,
129–130
in bipolar disorders, 226eating disorders and, 451
in personality disorders, 576
Autonomic nervous system
(ASN), 35–36
Aversive self-awareness, 453
Avoidance
behavior therapy for,
123–124, 123t
eating disorders and, 451
in posttraumatic stress
disorder, 311
in specifi c phobias, 295
Avoidant attachment, 25, 206
Avoidant personality disorder,
613–615, 619
dependent personality
disorder vs., 616
Avolition, 523
Axons, 38–39, 39f° B °
Barbiturates, 406–407, 697
Barzee, Wanda, 532
Basal ganglia, 37, 37f
in attention-defi cit/
hyperactivity disorder,
661
in eating disorders, 449
in obsessive-compulsive
disorder, 302–303, 303f
paraphilias and, 491
Baseline assessment, 179
Beale, Big Edie and Little Edie,
3–4, 4f, 7f, 9–10, 33–34
cognitive theory on, 24
distress shown by, 5
emotions of, 55–56
feedback loops affecting, 67
idiosyncracies of, 48
impairment of, 6
impulse control of, 26
negative punishment of, 51
observational learning by, 53
operant conditioning of, 50
risk of harm to, 7–8
social factors and, 60
social support of, 62–63
temperaments of, 58–59
Beatles, 381–382, 385, 391,
402, 412, 413–414
Beauty
eating disorders and norms
of, 458–460
in gender identity disorder,
479–480, 479f
Beckham, David, 304
Bedlam, 14
Bed nucleus of the stria
terminalis, 478
Bedwetting, 675–676, 675f
Behavior
antecedents of, 122–123
clinical assessment of, 95
consequences of, 122–123, 576
disorganized, 520–521, 523,
586
emotions and, 56learning and, 48–53
in personality disorders, 569
shaping, 126
stereotyped, 629–630, 635
Behavioral activation, 212–213
Behavioral genetics, 43–45
Behavioral inhibition, 282
Behaviorism, 22–23
Behavior modifi cation, 125–126
Behavior therapy, 122–125. See
also Cognitive-behavior
therapy (CBT)
effectiveness of, 180
for generalized anxiety
disorder, 258–259
for obsessive-compulsive
disorder, 305
for panic disorder, 273–274
Beliefs
assessing mental processes
and, 170
control, 130t
in personality disorders,
588–589
in posttraumatic stress
disorder, 312–313
in rational-emotive behavior
therapy, 128–129
in schizophrenia, 548–549
Bender Visual-Motor Gestalt
Test-II, 93–94
Benzedrine, 392
Benzodiazepines, 114, 407, 423,
697
for specifi c phobias, 292–293,
296
Bereavement, 195
Beta-blockers
for posttraumatic stress
disorder, 323
sexual dysfunction from, 506
for social phobia, 286
for substance use disorders,
423
Bias
assessing mental processes
and, 170
attentional, 203
child maltreatment and, 62
in clinical assessment, 95–96
in clinical interviews,
170–171
diagnostic, 76–77
emotions and, 56–57, 56f
experimenter expectancy
effects, 173
in experiments, 158–159
in facial expression
discrimination, 62
investigator-infl uenced,
173–174
in mental processes, 53–54, 55
mood-congruent memory, 170
reactivity, 173–174
reporting, 96–97
response, 171–172, 172f
sampling, 159